Intravesical Evans bacille Calmette-Guérin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group.
OBJECTIVE
To study the long-term results of a single 8 week course of intravesical Evans bacillus Calmette-Guérin (BCG) on carcinoma in situ (CIS) of the urinary bladder.


METHODS
This study reports on 43 patients who each received a single 8 week course of intravesical BCG.


RESULTS
In spite of the good initial complete response rate of 70%, the long-term follow-up was disappointing with half the patients either having recurrence or progression of their disease by 2 years. The patients had a close follow-up protocol with early radical treatment when disease progressed. The cause specific survival at 5 years was 70%.


CONCLUSIONS
We feel that similar future treatment protocols without maintenance treatment are not justified.
Department of Surgery/Urology, Western General Hospital, Edinburgh, UK.
R F
RF
Talic
T B
TB
Hargreave
M C
MC
Bishop
D
D
Kirk
S
S
Prescott
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D001500:BCG Vaccine